Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/28038
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia |
Author: | Livermore, D. Carter, M. Bagel, S. Wiedemann, B. Baquero, F. Loza, E. Endtz, H. van den Braak, N. Fernandes, C. Fernandes, L. Frimodt-Moller, N. Rasmussen, L. Giamarellou, H. Giamarellos-Bourboulis, E. Jarlier, V. Nguyen, J. Nord, C. Struelens, M. Nonhoff, C. Turnidge, J. et al. |
Citation: | Antimicrobial Agents and Chemotherapy, 2001; 45(6):1860-1867 |
Publisher: | Amer Soc Microbiology |
Issue Date: | 2001 |
ISSN: | 0066-4804 1098-6596 |
Statement of Responsibility: | David M. Livermore, Michael W. Carter, Simone Bagel, Bernd Wiedemann, Fernando Baquero, Elena Loza, Hubert P. Endtz, Nicole Van Den Braak, Clarence J. Fernandes, Lorna Fernandes, Niels Frimodt-Moller, Laura S. Rasmussen, Helen Giamarellou, Evangelos Giamarellos-Bourboulis, Vincent Jarlier, Jacqueline Nguyen, Carl-Erik Nord, Marc J. Struelens, Caire Nonhoff, John Turnidge, Jan Bell, Reinhard Zbinden, Stefan Pfister, Lori Mixson, and Daniel L. Shungu |
Abstract: | Ertapenem (MK-0826, L-749,345) is a 1-β-methyl carbapenem with a long serum half-life. Its in vitro activity was determined by broth microdilution against 3,478 bacteria from 12 centers in Europe and Australia, with imipenem, cefepime, ceftriaxone, and piperacillin-tazobactam used as comparators. Ertapenem was the most active agent tested against members of the familyEnterobacteriaceae, with MICs at which 90% of isolates are inhibited (MIC₉₀s) of ≤1 μg/ml for all species. Ertapenem also was more active than imipenem against fastidious gram-negative bacteria and Moraxella spp.; on the other hand, ertapenem was slightly less active than imipenem against streptococci, methicillin-susceptible staphylococci, and anaerobes, but its MIC₉₀s for these groups remained ≤0.5 μg/ml.Acinetobacter spp. and Pseudomonas aeruginosawere also much less susceptible to ertapenem than imipenem, and mostEnterococcus faecalis strains were resistant. Ertapenem resistance, based on a provisional NCCLS MIC breakpoint of ≥16 μg/ml, was seen in only 3 of 1,611 strains of the familyEnterobacteriaceae tested, all of them Enterobacter aerogenes. Resistance was also seen in 2 of 135 anaerobes, comprising 1 Bacteroides fragilis strain and 1Clostridium difficile strain. Ertapenem breakpoints for streptococci have not been established, but an unofficial susceptibility breakpoint of ≤2 μg/ml was adopted for clinical trials to generate corresponding clinical response data for isolates for which MICs were as high as 2 μg/ml. Of 234 Streptococcus pneumoniae strains tested, 2 required ertapenem MICs of 2 μg/ml and one required an MIC of 4 μg/ml, among 67 non-Streptococcus pyogenes, non-Streptococcus pneumoniae streptococci, single isolates required ertapenem MICs of 2 and 16 μg/ml. These streptococci also had diminished susceptibilities to other β-lactams, including imipenem as well as ertapenem. The Etest and disk diffusion gave susceptibility test results in good agreement with those of the broth microdilution method for ertapenem. |
Keywords: | Bacteria Carbapenems Anti-Bacterial Agents Microbial Sensitivity Tests Quality Control Australia Europe |
Rights: | Copyright © 2000, American Society for Microbiology. All Rights Reserved. |
DOI: | 10.1128/AAC.45.6.1860-1867.2001 |
Published version: | http://dx.doi.org/10.1128/aac.45.6.1860-1867.2001 |
Appears in Collections: | Aurora harvest 6 Molecular and Biomedical Science publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.